European Heart Journal Advance Access originally published online on April 2, 2007
European Heart Journal 2007 28(7):829-835; doi:10.1093/eurheartj/ehm033
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Increase in serum adiponectin concentration in patients with heart failure and cachexia: relationship with leptin, other cytokines, and B-type natriuretic peptide
1 BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, Scotland, UK
2 Institute of Biomedical and Life Sciences, University of Glasgow, Glasgow, Scotland, UK
3 Glasgow Royal Infirmary, Glasgow, Scotland, UK
4 Stobhill Hospital Glasgow, Glasgow, Scotland, UK
Received 25 September 2006; revised 5 February 2007; accepted 23 February 2007; online publish-ahead-of-print 2 April 2007.
* Corresponding author. Tel: +44 141 211 1838; fax: +44 141 211 2252. E-mail address: mbmcentegart{at}doctors.org.uk
Aims: Adiponectin is a fat-derived hormone involved in the regulation of metabolism. Adiponectin concentration is inversely related to body weight and, in animals, causes weight loss. We, therefore, measured adiponectin concentration in patients with heart failure (HF) and cachexia.
Methods and results: Serum adiponectin concentrations were measured in three groups of patients with coronary artery disease (CAD): (i) HF, reduced left ventricular systolic function, and cachexia (n = 10); (ii) HF, reduced systolic function but no cachexia (n = 20); (iii) HF-controls–patients with CAD, no HF, and preserved systolic function (n = 10); and in a healthy control group (n = 7). Patients with HF and cachexia had higher concentrations of adiponectin [23.8 (10.2–37.2) µg/mL] than all other groups: HF–no cachexia 8.1 (0.5–16.6) µg/mL; CAD-controls 7.1 (0.4–13.5) µg/mL; and healthy controls 8.7 (2.5–16.8) µg/mL) (P < 0.05 for each comparison). Adiponectin correlated negatively with body mass index, percentage of body fat, waist circumference and insulin resistance, and positively with B-type natriuretic peptide (BNP) and tumour necrosis factor-
.
Conclusion: Cachexia in HF is associated with an increase in adiponectin concentration. This may represent preservation of the physiological response to change in body fat but might also suggest that adiponectin plays a role in the pathogenesis of cachexia. The correlation between BNP and adiponectin also raises the possibility that the former might increase the secretion of the latter.
Key Words: Heart failure • Cachexia • Coronary artery disease • Adipose tissue • Metabolism • Adiponectin
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  N. Sattar and S. M. Nelson Adiponectin, Diabetes, and Coronary Heart Disease in Older Persons: Unraveling the Paradox J. Clin. Endocrinol. Metab., September 1, 2008; 93(9): 3299 - 3301. [Full Text] [PDF]
|
|
|
|
 |
|
 E. Braunwald Biomarkers in Heart Failure N. Engl. J. Med., May 15, 2008; 358(20): 2148 - 2159. [Full Text] [PDF]
|
|
|
|
|
|
N. Sattar, P. Watt, L. Cherry, S. Ebrahim, G. Davey Smith, and D. A. Lawlor High Molecular Weight Adiponectin Is Not Associated with Incident Coronary Heart Disease in Older Women: A Nested Prospective Case-Control Study J. Clin. Endocrinol. Metab., May 1, 2008; 93(5): 1846 - 1849. [Abstract] [Full Text] [PDF]
|
|